Marketing built for hormone clinics.

A hormone clinic is a subscription business. Almost every one of them is marketed like a one-off sale, and that single mismatch explains most of what goes wrong with the numbers.

The arithmetic is not subtle. If a program runs a few hundred dollars a month and acquisition costs several hundred, the first month does not cover the patient. Neither does the second, once product and clinician time are counted. The patient becomes profitable somewhere around month four or five and genuinely valuable after a year. Which means a clinic optimising for cost per lead is optimising the least important variable in its own business, and a clinic that acquires cheaply but loses patients at month three is going backwards while its dashboard looks healthy.

The lab gap is where sign-ups die

Ask most hormone clinics about their funnel and they will describe a leak between sign-up and first dose. A patient enrols while motivated, usually late at night, and then has to book a lab draw, wait for results, and get through a consult before anything actually happens. Two or three weeks pass. In most clinics that stretch is close to silent.

Motivation does not survive silence. The patient who was ready on Tuesday has, by the following Thursday, started wondering whether this is worth the money, whether the clinic is organised, and whether the cheaper option they scrolled past would have been simpler. Nothing has gone wrong clinically. The clinic simply stopped talking during the only period where the patient had nothing to hold onto.

Keeping that stretch populated fixes a large share of it. Clear expectations of what happens next and when, a nudge if the draw has not been booked, the results explained rather than dumped, and a consult that arrives when it was promised. This is the highest return work available in most hormone clinics and it requires no additional ad spend at all.

Competing with national telehealth

Every local hormone clinic is now advertising alongside national subscription brands with more budget and lower prices. Competing on price against them is a losing position and most clinics know it, but the alternative is often left vague.

The specific thing a national subscription cannot provide is a named clinician who knows the patient, labs and follow-up that happen in person, and dose adjustment handled by somebody who answers when something feels wrong. Those are ordinary features of a local practice and they matter enormously to one particular patient: the one who already tried a cheap subscription, got a standard protocol, felt no better, and stopped. That group grows every year, and they are a far better prospect than someone shopping hormone therapy for the first time on price.

Men’s and women’s programs also need separating. They are different patients with different symptoms, different objections, and different platform restrictions, and running them through one campaign produces a blended number that hides which is working and creative that speaks properly to neither.

Retention is an operations problem wearing marketing clothes

Patients rarely leave a hormone program because they decided against therapy. They leave because a refill ran out during a busy fortnight, or a side effect appeared and nobody was easy to reach, or three months passed with no contact and the charge started looking like a subscription they had forgotten to cancel.

All three are fixable with sequences rather than with staff time. Refills prompted before the patient runs out. Check-ins timed to the points where doubts and side effects typically show up. A fast, obvious route to a clinician. None of it is clever, and it is worth more than any improvement to the top of the funnel, because the same acquisition spend suddenly buys patients who stay twice as long.

We run the whole path as one system: compliant campaigns that survive the ad policies in this category, an intake that carries a patient through labs and results without going quiet, response times under a minute, refill and adherence sequences, continuity offers that give a reason to commit past the trial, and reporting tied to patients still on therapy at month six.

Ad spend stays separate and goes directly to the platforms. Engagements typically run $1,000 to $5,000 a month depending on service lines and locations.